Gene Delivery Technologies Market Report 2025

The gene delivery technologies market size has grown rapidly in recent years. It will grow from $3.79 billion in 2024 to $4.3 billion in 2025 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to enhanced understanding of genetic diseases, advancements in cell therapy, evolution of nanotechnology, growth of gene therapy trials, research funding increase.

The gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $7.44 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to precision medicine development, regulatory framework enhancements, proliferation of gene therapy, expansion of non-viral delivery systems. Major trends in the forecast period include application in rare diseases, rise in clinical trials, targeted drug delivery, expansion of cell therapy, development of gene editing tools.

The growing prevalence of cell and gene therapies is projected to drive the growth of the gene delivery technologies market in the future. Cell and gene therapies are medical treatments designed to cure or alleviate diseases by modifying the genetic and cellular composition of a patient’s body. The rise in these therapies is largely fueled by advancements in gene editing technologies, which play a crucial role in the development and commercialization of cell and gene therapies. For example, in August 2024, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported that the UK medicines regulator has historically approved an average of two advanced therapy medicinal products (ATMPs) annually. However, this number is expected to increase to 10-15 approvals per year by 2030. Additionally, the number of patients receiving these therapies in the UK could grow from 2,500 in 2021 to as many as 10,000 annually by 2028. Therefore, the rise in cell and gene therapies is a key factor driving the gene delivery technologies market.

The rising demand for personalized medicine is expected to drive the growth of the gene delivery technologies market in the future. Personalized medicine refers to a tailored healthcare approach that considers individual patient characteristics, such as genetics, environment, and lifestyle, to improve treatment effectiveness and outcomes. Several factors are contributing to the increased demand for personalized medicine, including advancements in genomics, greater patient empowerment, and enhanced treatment efficacy. Gene delivery technologies allow for the precise targeting of specific cells or tissues, ensuring that therapies are administered only where needed, which helps to minimize side effects and maximize therapeutic effectiveness. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to just six in 2022. Thus, the growing demand for personalized medicine is a significant driver of the gene delivery technologies market.

Technological advancement has become a prominent trend in the gene delivery technologies market. Major players in the market are directing their efforts toward the development of advanced products to fortify their market positions. For instance, in February 2023, Aera Therapeutics, a US-based biotechnology company, introduced Aera's Platform delivery technology, aiming to unlock the potential of genetic medicines. Aera's PNP technology facilitates precise targeting of RNA molecules implicated in disease processes, enabling the targeted editing of genes in a patient's cells and offering potential for personalized gene therapies.

Leading companies in gene delivery technologies are concentrating on the development of advanced products, such as the ProteoAnalyzer, to achieve a competitive advantage in the market. The ProteoAnalyzer is a sophisticated automated system created by Agilent Technologies specifically for protein analysis, utilizing parallel capillary electrophoresis (CE) technology. For example, in July 2024, Agilent Technologies Inc., a life sciences company based in the US, launched the ProteoAnalyzer system. This innovative platform is designed for automated parallel capillary electrophoresis, allowing for rapid and high-resolution protein analysis with minimal sample consumption. This feature is especially advantageous for researchers dealing with complex protein mixtures in pharmaceuticals, biopharma, and bioengineered food ingredients, enabling quicker discoveries and advancements in translational research. The system facilitates detailed analysis of protein mixtures, which is essential for the development of therapeutic proteins.

In January 2024, Kyowa Kirin Co. Ltd., a pharmaceutical company based in Japan, acquired Orchard Therapeutics plc for an undisclosed amount. This acquisition is intended to enhance Kyowa Kirin's gene therapy portfolio by utilizing Orchard Therapeutics' expertise in hematopoietic stem cell (HSC) gene therapies to tackle rare genetic diseases and broaden patient access to transformative treatments. Orchard Therapeutics plc is a biopharmaceutical company located in the UK that specializes in gene therapy.

Major companies operating in the gene delivery technologies market include Thermo Fisher Scientific Inc., QIAGEN NV, Horizon Discovery Group Co, OriGene Technologies Inc., Oxford Biomedica Solutions LLC, SignaGen Laboratories LLC, Vectalys SAS, Takara Bio Inc., Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Hoffmann-La Roche AG, Catalent Inc., Avantor, Pfizer Inc., Becton Dickinson and Company, Novartis AG, Intellia Therapeutics Inc., Editas Medicine Inc., CRISPR Therapeutics AG, Spark Therapeutics Inc., Bluebird Bio Inc., Sarepta Therapeutics Inc., Regenexxbio Inc., Beam Therapeutics Inc., Verve Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Translate Bio Inc., CureVac N.V., Lonza Group AG.

North America was the largest region in the gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global gene delivery technologies market report during the forecast period. The regions covered in the gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gene delivery technologies encompass methods utilized to introduce foreign genetic material, such as DNA or RNA, into cells, aiming to transfer the genetic material into the target cells. These technologies are commonly employed in the treatment of diseases or disorders resulting from altered genes, such as mutations or inherited genetic anomalies.

The primary types of gene delivery technologies modes include biological, chemical, and physical approaches. Biological methods involve the use of living organisms or their derivatives in the development and delivery of gene therapy products. Various techniques, such as ex vivo, in vivo, and in vitro applications, are employed in gene therapy, cell therapy, vaccines, and research.

The gene delivery technologies market research report is one of a series of new reports that provides gene delivery technologies market statistics, including gene delivery technologies industry global market size, regional shares, competitors with a gene delivery technologies market share, detailed gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the gene delivery technologies industry. This gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene delivery technologies market consists of revenues earned by entities by providing services such as viral vector production, gene editing, gene therapy, and cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Gene delivery technologies also include sales of viral and non-viral vectors, transfection reagents, gene editing tools that are used in providing gene delivery. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.